RecruitingNCT06843629

Clinical Application of PET Imaging Targeting MSLN in Malignant Tumors

Sponsor

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Enrollment

100 participants

Start Date

Oct 1, 2024

Study Type

OBSERVATIONAL

Conditions

Pancreatic Cancer Ovarian Cancer Lung Adenocarcinoma

Summary

The project aims to perform integrated PET/MR or PET/CT visualization of patients with clinically suspected or confirmed pancreatic cancer, ovarian cancer, lung adenocarcinoma and other malignant tumors with high MSLN expression and healthy volunteers, using targeted MSLN-specific imaging agents (taking \[68Ga\]Ga-NOTA-MSLN antibody fragment as an example), to achieve the following purposes: Patients with malignant tumors: for diagnosis and staging of diseases, comparing with the gold standard pathological diagnosis, evaluating diagnostic efficacy, clarifying the presence or absence of lesions, and determining the location and nature of lesions; comparing with \[18F\]FDG PET for accurate staging, evaluating the tumor load, and helping to determine the therapeutic plan. Healthy volunteers: Pharmacokinetic analysis will be performed to clarify the distribution and metabolism of the drug in the body and its safety.

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This study is using a special type of PET scan — a medical imaging test that uses a small amount of radioactive material — to look at tumors that express a protein called mesothelin (MSLN), which is found in several cancers including pancreatic, ovarian, and lung cancers. The goal is to see how well this new imaging approach can detect these tumors. **You may be eligible if...** - You are 18 or older - You have a known or suspected cancer that may express the mesothelin protein (e.g., pancreatic, ovarian, lung, mesothelioma) - You are able and willing to follow the study procedures **You may NOT be eligible if...** - You have severe kidney or liver problems that affect how your body processes the imaging agent - You are pregnant or breastfeeding - You are unable to provide informed consent Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTSpecific positron imaging agents targeting MSLN

To perform integrated PET/MR or PET/CT visualization of patients with clinically suspected or confirmed pancreatic cancer, ovarian cancer, lung adenocarcinoma and other malignant tumors with high MSLN expression and healthy volunteers, using specific positron imaging agents targeting MSLN (taking \[68Ga\]Ga-NOTA-MSLN antibody fragment as an example), to achieve the following purposes: Patients with malignant tumors: for diagnosis and staging of diseases, comparing with the gold standard pathological diagnosis, evaluating diagnostic efficacy, clarifying the presence or absence of lesions, and determining the location and nature of lesions; comparing with \[18F\]FDG PET for accurate staging, evaluating the tumor load, and helping to determine the therapeutic plan. Healthy volunteers: Pharmacokinetic analysis will be performed to clarify the distribution and metabolism of the drug in the body and its safety.